Shaun Fleming
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Shaun Fleming has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Andrew H. Wei
Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia
1 shared publication Andrew Spencer
Malignant Haematology Transplantation & Cellular Therapy Services, Alfred Hospital, VIC, Australia; Australian Centre for Blood Diseases, Monash University, VIC, Australia
1 shared publication- Andrew Spencer
Department of Malignant Haematology, The Alfred Hospital, Melbourne, Australia
1 shared publication - Anneke van der Walt
Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Australia
1 shared publication - Ashish Bajel
Clinical Hematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia
1 shared publication Björn Steffen
11Department of Medicine II, Hematology/Oncology, Goethe University Hospital, Frankfurt, Germany
1 shared publication
Latest Publications
- Open Access
- 27 November 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (4) , 436-445
Repeatable Battery for the Assessment of Neuropsychological Status: Preliminary Utility for Subacute Cognitive Monitoring after Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T-Cell Therapy
- 27 November 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (4) , 436-445
Open AccessRepeatable Battery for the Assessment of Neuropsychological Status: Preliminary Utility for Subacute Cognitive Monitoring after Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T-Cell Therapy
- Open Access
- 15 November 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (Supplement) , 6134-6136
Blinatumomab Alternating With Low-Intensity Chemotherapy (CT) Treatment for Older Adults With Newly Diagnosed Philadelphia (Ph)-Negative B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) is Well Tolerated and Efficacious: Safety Run-In Results for the Phase 3 Randomized Controlled Golden Gate Study
- 15 November 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (Supplement) , 6134-6136
Open AccessBlinatumomab Alternating With Low-Intensity Chemotherapy (CT) Treatment for Older Adults With Newly Diagnosed Philadelphia (Ph)-Negative B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) is Well Tolerated and Efficacious: Safety Run-In Results for the Phase 3 Randomized Controlled Golden Gate Study
- 14 July 2015
- Published by Wiley in Transfusion
- Vol. 55 (11) , 2709-2713
Comparison of biosimilar filgrastim with originator filgrastim for peripheral blood stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous stem cell transplantation
BACKGROUND: Nivestim is a biosimilar approved for the same indications as Neupogen including the mobilization of autologous peripheral blood stem cells (PBSCs). The clinical efficacy and safety of Nivestim for this use have not been formally assessed in clinical trials.STUDY DESIGN AND METHODS: In our retrospective single‐center study we compared variables of PBSC mobilization and engraftment of 60 patients mobilized with Nivestim to that of 38 patients mobilized with Neupogen.RESULTS: We found no difference between Nivestim and Neupogen in peripheral blood CD34+ at first leukapheresis (47 × 106 cells/L vs. 60 × 106 cells/L, p = 0.48) nor the total CD34+ collected (5.37 × 106/kg vs. 4.59 × 106/kg, p = 0.22). However, a difference in the median number of leukapheresis procedures (one vs. two, p = 0.0007) was observed. Eighty‐one patients (51 Nivestim and 30 Neupogen mobilized) went on to transplantation. Median time to neutrophil engraftment (15 days vs. 13.5 days, p = 0.09) and platelet (PLT) engraftment (20 days vs. 18 days, p = 0.01) was longer in the Nivestim group. The significant delay in PLT engraftment did not, however, translate to increased PLT transfusions (two vs. three, p = 0.2) or impact significantly on hospitalization time for admissions within 30 days posttransplant (20 days vs. 18 days, p = 0.17).CONCLUSION: Nivestim is as effective as Neupogen for PBSC mobilization; however, its use was associated with a delay in PLT recovery. A prospective study should be conducted to confirm our findings.
- 14 July 2015
- Published by Wiley in Transfusion
- Vol. 55 (11) , 2709-2713
Comparison of biosimilar filgrastim with originator filgrastim for peripheral blood stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous stem cell transplantation
BACKGROUND: Nivestim is a biosimilar approved for the same indications as Neupogen including the mobilization of autologous peripheral blood stem cells (PBSCs). The clinical efficacy and safety of Nivestim for this use have not been formally assessed in clinical trials.STUDY DESIGN AND METHODS: In our retrospective single‐center study we compared variables of PBSC mobilization and engraftment of 60 patients mobilized with Nivestim to that of 38 patients mobilized with Neupogen.RESULTS: We found no difference between Nivestim and Neupogen in peripheral blood CD34+ at first leukapheresis (47 × 106 cells/L vs. 60 × 106 cells/L, p = 0.48) nor the total CD34+ collected (5.37 × 106/kg vs. 4.59 × 106/kg, p = 0.22). However, a difference in the median number of leukapheresis procedures (one vs. two, p = 0.0007) was observed. Eighty‐one patients (51 Nivestim and 30 Neupogen mobilized) went on to transplantation. Median time to neutrophil engraftment (15 days vs. 13.5 days, p = 0.09) and platelet (PLT) engraftment (20 days vs. 18 days, p = 0.01) was longer in the Nivestim group. The significant delay in PLT engraftment did not, however, translate to increased PLT transfusions (two vs. three, p = 0.2) or impact significantly on hospitalization time for admissions within 30 days posttransplant (20 days vs. 18 days, p = 0.17).CONCLUSION: Nivestim is as effective as Neupogen for PBSC mobilization; however, its use was associated with a delay in PLT recovery. A prospective study should be conducted to confirm our findings.
- 1 August 2014
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 14 (4) , 291-296
The Choice of Multiple Myeloma Induction Therapy Affects the Frequency and Severity of Oral Mucositis After Melphalan-Based Autologous Stem Cell Transplantation
- 1 August 2014
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 14 (4) , 291-296
The Choice of Multiple Myeloma Induction Therapy Affects the Frequency and Severity of Oral Mucositis After Melphalan-Based Autologous Stem Cell Transplantation